Comprehensive Guide to Levonorgestrel: Uses, Dosage, Side Effects, and More
What is Levonorgestrel?
Overview of Levonorgestrel
Generic Name: Levonorgestrel
Brand Name: Plan B One-Step, Mirena, Kyleena, generics
Drug Group: Progestin (contraceptive, emergency contraception)
Commonly Used For
- Prevent pregnancy after unprotected intercourse.
- Provide long-term contraception via IUD.
- Manage heavy menstrual bleeding.
Key Characteristics
Form: Oral tablets (0.75 mg, 1.5 mg), intrauterine devices (52 mg, 19.5 mg), or implants (detailed in Dosage section).
Mechanism: Suppresses gonadotropin release, preventing ovulation and fertilization.
Approval: FDA-approved (1999 for Plan B) and EMA-approved for contraception.

Indications and Uses of Levonorgestrel
Levonorgestrel is indicated for a variety of reproductive health conditions, leveraging its potent progestogenic effects:
Emergency Contraception: Prevents pregnancy within 72–120 hours after unprotected sex, per gynecology guidelines, supported by clinical trials showing 85–95% efficacy when taken within 24 hours.
Long-Term Contraception: Provides up to 3–8 years of pregnancy prevention via IUD (Mirena, Kyleena), recommended in family planning protocols with evidence of reduced unintended pregnancies.
Heavy Menstrual Bleeding (HMB): Manages menorrhagia by reducing menstrual blood loss, improving quality of life, with gynecologic data.
Endometriosis: Investigated off-label to alleviate pelvic pain and lesion progression, with reproductive endocrinology studies.
Dysmenorrhea: Used off-label to reduce painful periods, supported by pain management research.
Hormone Replacement Therapy (HRT): Applied off-label in postmenopausal women with a uterus, with endocrinology evidence.
Polycystic Ovary Syndrome (PCOS): Explored off-label to regulate cycles and reduce androgen levels, with endocrinology-gynecology data.
Postpartum Contraception: Initiated off-label via IUD insertion post-delivery, with obstetrics studies.
Ovarian Cyst Prevention: Investigated off-label to reduce functional cyst formation, with gynecologic research.
Adenomyosis: Managed off-label to decrease uterine pain and bleeding, with imaging-supported evidence.
Dosage of Levonorgestrel
Dosage for Adults
Emergency Contraception:
- Oral: 1.5 mg as a single dose or 0.75 mg within 72 hours followed by another 0.75 mg 12 hours later, taken within 120 hours of unprotected intercourse.
Long-Term Contraception (IUD):
- Mirena (52 mg): Inserted into the uterus, effective for up to 8 years.
- Kyleena (19.5 mg): Inserted, effective for up to 5 years.
Heavy Menstrual Bleeding:
- Mirena (52 mg): Inserted, reduces bleeding within 3–6 months, maintained for up to 5 years.
Dosage for Adolescents (≥15 years)
Emergency Contraception: Oral: 1.5 mg as a single dose, under gynecologic supervision.
Long-Term Contraception: Mirena or Kyleena: Inserted with parental consent and monitoring.
Dosage for Pregnant Women
Pregnancy Category X: Contraindicated if pregnancy is confirmed; consult an obstetrician for removal if IUD is in place, with fetal monitoring if exposure occurs.
Dosage Adjustments
Renal Impairment: No adjustment needed; monitor for systemic effects in severe cases.
Hepatic Impairment: Mild to moderate (Child-Pugh A or B): Use cautiously; severe (Child-Pugh C): Avoid due to metabolism concerns.
Concomitant Medications: Adjust if combined with enzyme inducers (e.g., rifampin), reducing efficacy; monitor.
Elderly: Not typically indicated; assess for contraindications if used.
Body Weight: Efficacy may decrease in women >75 kg for emergency use; consider copper IUD as an alternative.
Additional Considerations
- Take this active ingredient orally with or without food for emergency use; IUD insertion requires a trained provider.
- Check IUD strings monthly to ensure proper placement.
- Use backup contraception for 7 days after emergency use if ovulation is possible.
How to Use Levonorgestrel
Administration:
- Oral: Swallow tablet whole with water, taken as soon as possible after unprotected sex.
- IUD: Inserted by a healthcare provider into the uterine cavity using a sterile technique.
Timing: Take emergency dose within 120 hours; IUD provides continuous release over years.
Monitoring: Watch for abdominal pain, irregular bleeding, or signs of infection (e.g., fever); report changes immediately.
Additional Tips:
- Store at 20–25°C (68–77°F), protecting from light and moisture.
- Keep out of reach of children; dispose of unused tablets per local regulations.
- Educate patients on IUD removal signs (e.g., expulsion, pain) and emergency contact protocols.
- Schedule follow-up visits at 4–6 weeks post-IUD insertion and annually to assess placement and side effects.
- Avoid douching or using tampons immediately after IUD insertion to reduce infection risk.
Contraindications for Levonorgestrel
Hypersensitivity: Patients with a known allergy to Levonorgestrel or IUD components.
Pregnancy: Contraindicated if pregnancy is confirmed due to teratogenic risk.
Undiagnosed Abnormal Uterine Bleeding: Avoid until etiology is determined to prevent masking serious conditions.
Breast Cancer: Contraindicated in current or recent breast cancer due to hormonal stimulation risk.
Liver Tumors or Disease: Avoid in active hepatic adenoma or severe liver disease (Child-Pugh C).
Uterine Abnormalities: Contraindicated in distorted uterine cavity or acute pelvic inflammatory disease (PID).
Recent Septic Abortion: Avoid within 3 months due to infection risk.
Congenital Heart Disease: Contraindicated in patients with Eisenmenger syndrome due to hemodynamic concerns.
Side Effects of Levonorgestrel
Common Side Effects
- Irregular Bleeding (20–30%, stabilizes over months)
- Abdominal/Pelvic Pain (10–20%, managed with rest)
- Headache (5–15%, relieved with hydration)
- Nausea (5–10%, decreases with food)
- Breast Tenderness (3–8%, subsides with time)
These effects may subside with adaptation.
Serious Side Effects
Seek immediate medical attention for:
- Reproductive: Ectopic pregnancy or uterine perforation.
- Infectious: PID or endometritis with IUD.
- Cardiovascular: Thromboembolism or stroke (rare).
- Hepatic: Jaundice or liver dysfunction.
- Allergic: Rash, angioedema, or anaphylaxis.
Additional Notes
- Regular monitoring with pelvic exams and ultrasound every 6–12 months is advised for IUD users.
- Patients with a history of depression should be watched for mood changes, with psychiatric referral if needed.
- Report any unusual symptoms (e.g., severe pelvic pain, chest pain) immediately to a healthcare provider.
- Long-term IUD use (>5 years) requires assessing for expulsion or embedment with imaging.
Warnings & Precautions for Levonorgestrel
General Warnings
Ectopic Pregnancy: Increased risk if pregnancy occurs; monitor for abdominal pain or missed periods.
Ovarian Cysts: Risk of functional cysts with IUD use; perform pelvic exams if suspected.
Uterine Perforation: Rare risk during IUD insertion; assess post-procedure.
Infection: Risk of PID within first 20 days post-IUD insertion; monitor for fever or discharge.
Mood Changes: Risk of depression or anxiety; assess mental health.
Additional Warnings
Thromboembolic Disorders: Rare risk; discontinue if sudden chest pain or leg swelling occurs.
Liver Function: Risk of enzyme elevation; monitor in hepatic impairment.
Breast Tenderness: Common side effect; reassure patients.
Weight Gain: Possible with long-term use; monitor BMI.
Hypersensitivity Reactions: Rare anaphylaxis; stop if severe.
Use in Specific Populations
- Pregnancy: Category X; remove IUD if pregnancy occurs.
- Breastfeeding: Use caution; monitor infant for hormonal effects.
- Elderly: Not typically indicated; assess risks if used.
- Adolescents: Safe for IUD with consent and monitoring.
- Renal/Hepatic Impairment: Adjust or avoid in severe cases.
Additional Precautions
- Inform your doctor about liver disease, recent pregnancy, or bleeding disorders before starting this medication.
- Avoid smoking to reduce thrombotic risk during IUD use.
- Use condoms if STI risk is present to complement IUD protection.
Overdose and Management of Levonorgestrel
Overdose (from excessive oral intake) may cause:
- Nausea, vomiting, or vaginal bleeding.
- Severe cases: Hormonal overload (e.g., breast tenderness, dizziness) or liver strain.
- Abdominal pain or fatigue as early signs.
- Rare coma or profound hormonal imbalance with extremely high doses.
Immediate Actions
Contact the Medical Team: Seek immediate medical help if overdose is suspected.
Supportive Care: Monitor vital signs, provide antiemetics if needed, and observe for 24 hours.
Specific Treatment: No specific antidote; supportive care and observation are sufficient.
Monitor: Check liver function and hormone levels (e.g., progesterone) for 24–48 hours.
Patient Education: Advise against taking multiple doses and to store safely.
Additional Notes
- Overdose risk is low with proper use; systemic absorption from IUD is minimal.
- Report persistent symptoms (e.g., severe abdominal pain, irregular bleeding) promptly.
Drug Interactions with Levonorgestrel
This active ingredient may interact with:
- CYP3A4 Inducers: Reduces efficacy (e.g., rifampin, St. John’s Wort); use backup contraception.
- Anticonvulsants: Decreases levels (e.g., phenytoin); monitor.
- Antiretrovirals: Alters metabolism (e.g., ritonavir); adjust dose.
- Hormonal Therapies: Potentiates effects (e.g., estrogen); monitor.
- Antibiotics: Minor effect (e.g., ampicillin); use caution.
Action: Provide your healthcare provider with a complete list of medications.
Patient Education or Lifestyle
Medication Adherence: Use this progestin as prescribed for contraception or bleeding, following the schedule.
Monitoring: Report irregular bleeding, pelvic pain, or signs of infection immediately.
Lifestyle: Avoid smoking to reduce thrombotic risk; maintain a balanced diet.
Diet: No specific restrictions; take oral dose with food if nauseated.
Emergency Awareness: Know signs of ectopic pregnancy or IUD displacement; seek care if present.
Follow-Up: Schedule check-ups at 4–6 weeks post-IUD and annually to monitor placement and health.
Pharmacokinetics of Levonorgestrel
Absorption: Oral, peak at 1–2 hours; IUD provides sustained release (10–20 µg/day initially).
Distribution: Volume of distribution ~1.8 L/kg; 50% protein-bound.
Metabolism: Hepatic via CYP3A4 to inactive metabolites.
Excretion: Primarily renal (as glucuronides); half-life 24–36 hours.
Half-Life: 24–36 hours, with prolonged effect from IUD.
Pharmacodynamics of Levonorgestrel
This drug exerts its effects by:
- Inhibiting ovulation by suppressing LH surge via hypothalamic-pituitary axis.
- Thickening cervical mucus to block sperm penetration.
- Altering endometrial lining to prevent implantation.
- Exhibiting dose-dependent risks of irregular bleeding and hormonal side effects.
Storage
- Temperature: Store at 20–25°C (68–77°F); protect from light and moisture.
- Protection: Keep in original packaging, away from heat.
- Safety: Store in a secure location out of reach of children and pets.
- Disposal: Dispose of unused tablets or IUD packaging per local regulations or consult a pharmacist.
Frequently Asked Questions (FAQs)
Q: What does Levonorgestrel treat?
A: This medication prevents pregnancy and manages heavy periods.
Q: Can this active ingredient cause irregular bleeding?
A: Yes, irregular bleeding is common; consult if persistent.
Q: Is Levonorgestrel safe for adolescents?
A: Yes, with supervision.
Q: How is this drug taken?
A: Orally or via IUD, as directed.
Q: How long is Levonorgestrel effective?
A: Up to 8 years with IUD, or 120 hours for emergency use.
Q: Can I use Levonorgestrel if pregnant?
A: No, it’s contraindicated; consult a doctor.
Regulatory Information
This medication is approved by:
U.S. Food and Drug Administration (FDA): Approved in 1999 (Plan B) for emergency contraception.
European Medicines Agency (EMA): Approved for contraception and menorrhagia.
Other Agencies: Approved globally for reproductive health; consult local guidelines.
References
- U.S. Food and Drug Administration (FDA). (2023). Plan B One-Step (Levonorgestrel) Prescribing Information.
- Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
- European Medicines Agency (EMA). (2023). Levonorgestrel Summary of Product Characteristics.
- EMA’s comprehensive information on the medication’s indications and precautions in Europe.
- National Institutes of Health (NIH). (2023). Levonorgestrel: MedlinePlus Drug Information.
- NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
- World Health Organization (WHO). (2023). WHO Model List of Essential Medicines: Levonorgestrel.
- WHO’s inclusion of Levonorgestrel for emergency contraception.
- Contraception Journal. (2022). Levonorgestrel IUD Efficacy.
- Peer-reviewed article on Levonorgestrel efficacy (note: access may require a subscription).